<?xml version='1.0' encoding='utf-8'?>
<document id="21659627"><sentence text="Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants."><entity charOffset="18-26" id="DDI-PubMed.21659627.s1.e0" text="brivanib" /><entity charOffset="54-63" id="DDI-PubMed.21659627.s1.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.21659627.s1.e0" e2="DDI-PubMed.21659627.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21659627.s1.e0" e2="DDI-PubMed.21659627.s1.e1" /></sentence><sentence text="Brivanib alaninate is the orally available prodrug of brivanib, a dual inhibitor of fibroblast growth factor and vascular endothelial growth factor signaling pathways that is under therapeutic investigation for various malignancies"><entity charOffset="0-18" id="DDI-PubMed.21659627.s2.e0" text="Brivanib alaninate" /><entity charOffset="54-62" id="DDI-PubMed.21659627.s2.e1" text="brivanib" /><pair ddi="false" e1="DDI-PubMed.21659627.s2.e0" e2="DDI-PubMed.21659627.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21659627.s2.e0" e2="DDI-PubMed.21659627.s2.e1" /></sentence><sentence text=" Brivanib alaninate inhibits CYP3A4 in vitro, and thus there is potential for drug-drug interaction with CYP3A4 substrates, such as midazolam"><entity charOffset="132-141" id="DDI-PubMed.21659627.s3.e0" text="midazolam" /></sentence><sentence text=" The present study evaluated pharmacokinetic parameters and safety/tolerability upon coadministration of brivanib alaninate and midazolam"><entity charOffset="105-123" id="DDI-PubMed.21659627.s4.e0" text="brivanib alaninate" /><entity charOffset="128-137" id="DDI-PubMed.21659627.s4.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.21659627.s4.e0" e2="DDI-PubMed.21659627.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21659627.s4.e0" e2="DDI-PubMed.21659627.s4.e1" /></sentence><sentence text=" Healthy participants received intravenous (IV) or oral midazolam with and without oral brivanib alaninate"><entity charOffset="56-65" id="DDI-PubMed.21659627.s5.e0" text="midazolam" /><entity charOffset="88-106" id="DDI-PubMed.21659627.s5.e1" text="brivanib alaninate" /><pair ddi="false" e1="DDI-PubMed.21659627.s5.e0" e2="DDI-PubMed.21659627.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21659627.s5.e0" e2="DDI-PubMed.21659627.s5.e1" /></sentence><sentence text=" Blood samples for pharmacokinetic analysis were collected up to 12 hours after midazolam and up to 48 hours after brivanib alaninate" /><sentence text=" Twenty-four participants were administered study drugs; 21 completed the trial" /><sentence text=" No clinically relevant effect of brivanib alaninate on the overall exposure to midazolam following IV or oral administration was observed"><entity charOffset="34-52" id="DDI-PubMed.21659627.s8.e0" text="brivanib alaninate" /></sentence><sentence text=" Orally administered brivanib alaninate was generally well tolerated in the presence of IV or oral midazolam"><entity charOffset="21-39" id="DDI-PubMed.21659627.s9.e0" text="brivanib alaninate" /><entity charOffset="99-108" id="DDI-PubMed.21659627.s9.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.21659627.s9.e0" e2="DDI-PubMed.21659627.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21659627.s9.e0" e2="DDI-PubMed.21659627.s9.e1" /></sentence><sentence text=" The lack of a pharmacokinetic interaction between brivanib and midazolam indicates that brivanib alaninate does not influence either intestinal or hepatic CYP3A4 and confirms that brivanib alaninate may be safely coadministered with midazolam and other CYP3A4 substrates"><entity charOffset="64-73" id="DDI-PubMed.21659627.s10.e0" text="midazolam" /><entity charOffset="181-199" id="DDI-PubMed.21659627.s10.e1" text="brivanib alaninate" /><entity charOffset="234-243" id="DDI-PubMed.21659627.s10.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.21659627.s10.e0" e2="DDI-PubMed.21659627.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21659627.s10.e0" e2="DDI-PubMed.21659627.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21659627.s10.e0" e2="DDI-PubMed.21659627.s10.e2" /><pair ddi="false" e1="DDI-PubMed.21659627.s10.e1" e2="DDI-PubMed.21659627.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21659627.s10.e1" e2="DDI-PubMed.21659627.s10.e2" /></sentence><sentence text="" /></document>